Clinical Trial Title RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Trial Status Open to Enrollment
Start Date 01/20/2021
Location hospitals
Trial Type Cancer - Adult Oncology
Specific Condition Lung Cancer
Description This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Eligibility Criteria

Eligibility Criteria

  • Pathologically proven diagnosis of extensive stage small cell lung cancer
  • Patients must be randomized within 9 weeks of last dose of etoposide/platinum or 6 weeks from completion of PCI
  • At the time of enrollment, patients must have had measurable disease (per RECIST) and 3 or fewer observable liver metastases and no evidence of progressive disease (per RECIST) at time of enrollment
  • History/physical examination within 14 days prior to registration
  • Imaging within 42 days prior to registration to include:
  •   MRI brain with contrast or CT Brain with contrast
  •   CT chest, abdomen and pelvis or whole body PET/CT scan after the fourth cycle of chemotherapy
  • Age ≥ 18
  • ECOG Performance Status of 0-2 at the time of registration

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number Central IRB
Notes Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial - Full Text View -
Principal Investigator Andrew Kee, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail